anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain a new elastase inhibitor derived from a natural substance having high safety, a skin care preparation for external use and a health food both containing the same.  <P>SOLUTION: The elastase inhibitor is an elastase inhibitor containing an extract of pine bark, especially the elastase inhibitor containing an extract of pine bark obtained by extraction with hot water has high effect. The skin care preparation for external use is obtained by using the extract that is also useful due to its moisture retaining effect. The health food is obtained by using the extract. Since the elastase inhibitor is derived from the natural substance, the skin care preparation for external use and the health food using the elastase inhibitor are safe ones.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Neurogenic lower urinary tract dysfunction in multiple sclerosis is often underestimated, underdiagnosed, and inadequately treated. Depending on the course of the disease and the location of neural damage, it occurs with varying frequency and types of impairment of urine storage and voiding function. Symptoms such as urinary incontinence, recurrent urinary tract infections, urgency, pollakiuria, reduced urinary flow, hesitancy as well as postvoid residual urine may occur. However, the symptoms do not allow any conclusions to be drawn about the underlying type of neurogenic lower urinary tract dysfunction. Although numerous data, publications, and guidelines are available on this topic today, there continues to be a lack of standardized screening parameters and algorithms that have been tested in prospective studies for multiple sclerosis. This article presents the current diagnostic and therapeutic options of neurogenic lower urinary tract dysfunction in multiple sclerosis. A crucial issue is the initial delay in diagnosis, not least due to a lack of communication between neurologists and urologists. Initial indicators of the presence of neurogenic lower urinary tract dysfunction can be obtained by actively asking about the subjective presence of symptoms such as urinary incontinence or the occurrence of urinary tract infections. However, a subjective lack of symptoms does not rule out a neurogenic lower urinary tract dysfunction. Regardless of the stage of the disease, an early and individualized neuro-urological diagnosis and treatment should be implemented. All aspects of the damage and the extent of functional deficits in other organ systems caused by multiple sclerosis must be included in this neuro-urological treatment decision, which requires a consistent interdisciplinary exchange between neurologists, general practitioners, and urologists. This interdisciplinary and interprofessional way of thinking and acting is key for an optimal treatment using the numerous therapeutic procedures. Lifelong, individual, risk-adapted urological care for the early detection and prevention of neuro-urological complications should be offered to persons with multiple sclerosis.
Vancomycin Hydrochloride for Oral Solution is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile. Parenteral administration of vancomycin is not effective for the above indications;

therefore, Vancomycin Hydrochloride for Oral Solution must be given orally for these infections. Orally administered Vancomycin Hydrochloride for Oral Solution is not effective for other types of infection.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Oral Solution and other antibacterial drugs, Vancomycin Hydrochloride for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
The Shanghai Elbow Dysfunction Score (SHEDS) is originally developed in English to evaluate joint function in patients with elbow stiffness. The purpose of this study is to translate and cross-culturally adapt the SHEDS instrument into Turkish and investigate its psychometric properties. Approximately seventy patients with elbow limitation will be included. For cross-cultural adaptation, two bi-lingual translators will use the back-translation procedure. Within a 3-to-5-day period after the first assessment, the participants will complete the Turkish version of SHEDS (SHEDS-T) to evaluate test-retest reliability. Cronbach's alpha (α) will use to assess internal consistency. The correlation with the Turkish version of the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, the Turkish version of Mayo Elbow Performance Score, and Short Form-12 will be determined to check the validity. Responsiveness and floor and ceiling effects will be detected.
Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
The invention belongs to the technical field of traditional Chinese medicines and preparation, and discloses a preparation for treating lung diseases and a preparation method thereof. The preparation is prepared by mixing various conventional Chinese herbal medicines with abundant resources and moderate drug effect compatibility. The compatibility of the medicinal materials in the preparation is equivalent, and the function of mutual fusion of the medicinal materials is obviously enhanced, so that the effects of nourishing yin, dissipating heat, dispelling cold, relieving exterior syndrome, clearing heat, removing toxicity, promoting blood circulation, removing blood stasis and relieving ulcer and counteracting toxic substances are achieved. Meanwhile, under the effective cooperation of various medicinal materials, the discomfort of the diseased region of the lung of a patient is obviously reduced until the diseased region is healed, and the Chinese medicinal composition has extremely high curative effect on pulmonary nodules, lung tumors, pulmonary tuberculosis, chronic obstructive pulmonary disease, silicosis, asthma and the like. The preparation method of the preparation has the advantages of simple operation process, less operation equipment, low requirement on operators and low cost. The Chinese medicinal preparation has the advantages of small external dosage, safety, reliability, no irritation, no dependence, no toxic or side effect, and suitability for individuals of all ages.
PURPOSE:To obtain the title surfactant having excellent properties as a cationic surfactant and mildly acting on the skin or the like by reacting a specified tert. amine compound with a poly(N-acylalkyleneimine) obtained by a specified production process. CONSTITUTION:A tert. amine compound having at least one 8-24C alkyl, aralkyl, aryl or like group (e.g. dimethyloctylamine) is reacted with a poly(N- acylalkyleneimine) obtained by polymerizing a cyclic imino ether compound of formula I (wherein R5 is H, 1-22C alkyl, cycloalkyl, aralkyl or aryl; and n is 2 or 3) through ring opening to obtain a cationic surfactant comprising a poly(N-acylalkyleneimine) derivative of a molecular weight of 200-20000, represented by formula II [wherein R1, R2 and R3 are each 1-24C alkyl, aralkyl or aryl; at least one of them is an 8-24C group; R4 is H or 1-3C alkyl; Y(-) is a counter ion of a quat. ammonium salt; X is a repeating N-acylalkyleneimine unit; and m is the degree of polymerization of poly(N-acylalkyleneimine)].
Compositions and methods for improved Adoptive Cell Therapy (ACT) are provided. Compositions of CAR-T cells including CAR modified by fusion with one or more copies of a polypeptide including from between 50 and 500 amino acids derived from intrinsically disordered regions (IDRs) of proteins are described. CAR-IDR-T cells have improved condensation of CAR and T cell activation, and overall enhanced anti-tumor efficacy as compared with CAR-T cells lacking the IDR domain(s). In preferred embodiments, CAR-IDR fusion peptides include an IDR domain of any of SEQ ID NOs.1-6. The compositions and methods provide enhanced CAR-T cell therapy for cancer as well as other disease and disorders. Also disclosed are genetically modified cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders.
During Part 2, participants receive matched placebo to adavosertib BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Several studies have shown a higher risk of liver cancer from indeterminate liver nodules, but the exact occurrence and predictors of liver cancer in this group are still unclear. Our aim is to study the development of liver cancer in this population and identify any potential risk factors.
METHODS: This retrospective study evaluated cirrhotic patients with indeterminate liver nodules from 2013 to 2023.Data from electronic patient records was analyzed to assess the association between HCC and baseline factors. Subgroup exploratory analysis compared characteristics of patients with de novo HCC and those with nodule transformation HCC.
RESULTS: Out of 116 patients with liver nodules, 19 (16%) developed HCC in up to 7.5-year follow-up. Univariate Cox regression analysis showed a significant association between HCC incidence and smoking [hazard ratio (HR) 2.60, 95% Confidence Interval [CI] 1.01-6.74), nodule diameter exceeding 2 cm (HR 5.41, 95% CI 1.45-20.18), and baseline LI-RADS score 3 (HR 3.78, 95% CI 1.36-19.52). Multivariate Cox regression analysis revealed significant independent associations with nodule diameters 1 cm to < 2 cm (adjusted HR 3.35, 95% CI 1.06-10.60) and greater than 2 cm (adjusted HR 5.85, 95% CI 1.10-31.16), as well as with LI-RADS 3 lesions (adjusted HR 3.75, 95% CI 1.16-12.11) with adjusting other potential predictors and covariates.
CONCLUSION: Our findings show a higher incidence of HCC in patients with indeterminate liver nodules, increasing over time and reaching 30% at seven years. Nodules larger than 1-2 cm or LI-RADS 3 lesions pose increased risk for HCC. Enhanced surveillance is necessary given the lack of clear management guidelines.
The research, will last for ten months at the Limit Institute of Health Sciences in Sahiwal, is a randomized controlled trial. With 10 participants in each group using a non-probability convenient sampling procedure, the sample size includes 10% attrition. Computer users between the ages of 18 and 35 who work five to seven hours a day meet the inclusion criteria, but recent musculoskeletal injuries and a history of head or spine trauma are the exclusion criteria. One instrument used to collect data is the Neck Disability Index (NDI). There are two established study groups: Group B will receive Muscle Energy Technique (MET) and traditional physiotherapy, while Group A will receive Bowen therapy and conventional physiotherapy. Blinding will be used, and the study will adhere to a recruitment, enrollment, and randomization procedure. SPSS version 23 will be used to analyze the data, and descriptive statistics, change over temporal analysis as well as tests of group comparison. The purpose of the study is to evaluate how the interventions affect people who use computers for extended periods in terms of their functional results and mechanical neck discomfort.
Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
PURPOSE: To build an Mult-Task Learning (MTL) based Artificial Intelligence(AI) model that can simultaneously predict clinical stage, histology, grade and LNM for cervical cancer before surgery.
METHODS: This retrospective and prospective cohort study was conducted from January 2001 to March 2014 for the training set and from January 2018 to November 2021 for the validation set at Beijing Chaoyang Hospital, Capital Medical University. Preoperative clinical information of cervical cancer patients was used. An Artificial Neural Network (ANN) algorithm was used to build the MTL-based AI model. Accuracy and weighted F1 scores were calculated as evaluation indicators. The performance of the MTL model was compared with Single-Task Learning (STL) models. Additionally, a Turing test was performed by 20 gynecologists and compared with this AI model.
RESULTS: A total of 223 cervical cancer cases were retrospectively enrolled into the training set, and 58 cases were prospectively collected as independent validation set. The accuracy of this cervical cancer AI model constructed with ANN algorithm in predicting stage, histology, grade and LNM were 75%, 95%, 86% and 76%, respectively. And the corresponding weighted F1 score were 70%, 94%, 86%, and 76%, respectively. The average time consumption of AI simultaneously predicting stage, histology, grade and LNM for cervical cancer was 0.01s (95%CI: 0.01-0.01) per 20 patients. The mean time consumption doctor and doctor with AI were 581.1s (95%CI: 300.0-900.0) per 20 patients and 534.8s (95%CI: 255.0-720.0) per 20 patients, respectively. Except for LNM, both the accuracy and F-score of the AI model were significantly better than STL AI, doctors and AI-assisted doctors in predicting stage, grade and histology. (P < 0.05) The time consumption of AI was significantly less than that of doctors' prediction and AI-assisted doctors' results. (P < 0.05 CONCLUSION: A multi-task learning AI model can simultaneously predict stage, histology, grade, and LNM for cervical cancer preoperatively with minimal time consumption. To improve the conditions and use of the beneficiaries, the model should be integrated into routine clinical workflows, offering a decision-support tool for gynecologists. Future studies should focus on refining the model for broader clinical applications, increasing the diversity of the training datasets, and enhancing its adaptability to various clinical settings. Additionally, continuous feedback from clinical practice should be incorporated to ensure the model's accuracy and reliability, ultimately improving personalized patient care and treatment outcomes.
The following adverse reactions have been identified during post-approval use of BOTOX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include: abdominal pain; alopecia, including madarosis; anorexia; brachial plexopathy; denervation/muscle atrophy; diarrhea; dry eye; eyelid edema (following periocular injection); hyperhidrosis; hypoacusis; hypoaesthesia; localized muscle twitching; malaise; Mephisto sign; paresthesia; peripheral neuropathy; radiculopathy; erythema multiforme, dermatitis psoriasiform, and psoriasiform eruption; strabismus; tinnitus; and visual disturbances.

There have been spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin [see Warnings and Precautions (5.4, 5.6)].

There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.

New onset or recurrent seizures have also been reported, typically in patients who are predisposed to experiencing these events. The exact relationship of these events to the botulinum toxin injection has not been established.
Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the white noise listening group.Before the intervention , a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
An open label, non randomized crossover phase 2 study to assess the PK of AP-CD/LD given at dose of 50/500mg three times daily compared to CD/LD immediate release (Sinemet) 1.5 tablets of dose of 25/100 given 5 times per day in Parkinson's Disease patients. The study will have a screening period followed by an overnight stay in clinic where Immediate release CD/LD (Sinemet) will be administered five times, approximately every three hours. At specified intervals, blood will be drawn for PK testing. On Days 2-7, subjects will be treated at home with AP CD/LD three times/day, approximately every five hours. Day 8 will be overnight stay in clinic for PK study. AP CD/LD 500mg TID will be dispensed to subjects with specified timelines for PK assessment. Each subject will return to clinic on day 15 for a safety followup visit.
Disclosed are polypeptides comprising an engineered recombinant EPO. For example, disclosed are polypeptides comprising the sequence of SEQ ID NO: 1. Disclosed are variant Epo polypeptides comprising three amino acid substitutions at positions 20, 45 and 97 of wild type human Epo. Disclosed are polynucleotides comprising a nucleic acid capable of encoding one or more of the disclosed polypeptides. Disclosed are vectors comprising any of the polynucleotides disclosed herein. Disclosed are compositions comprising the disclosed polypeptides, polynucleotides or vectors. Disclosed are cells comprising one or more of the disclosed polypeptides, one or more of the disclosed polynucleotides, and/or one or more of the disclosed vectors. Disclosed are methods of using a therapeutically effective amount of one or more of the disclosed polypeptides, nucleic acids or vectors to a subject in need thereof.
PROBLEM TO BE SOLVED: To obtain an aerosol type hair treatment composition which is a spray foam type composition that is jetted in the spray state from nozzles of aerosol vessels, adheres in the foam state when arriving at hair, loses the foams at a moderate rate and has good accommodation to hair, and in which, fine foams are evenly and homogeneously applied to hair and smoothness and gloss are given to hair. SOLUTION: This aerosol type hair treatment composition includes (A) 0.05-5 pts.wt. of a sugar fatty acid ester with HLB of 8-19, (B) 0.05-15 wt.% of a hydrophilic nonionic surfactant, (C) 1-50 pts.wt. of a lower alcohol, (D) 0.1-30 wt. of an oil agent and (E) water and is a mixture between a raw solution of an oil-in-water type emulsion composition and an aerosol propellant which is 100 pts.wt. in the total amount. The mixture weight ratio (raw solution/ aerosol propellant) is in the range of 40/60 to 80/20.
INTRODUCTION: Human papillomavirus (HPV) poses a substantial but underestimated healthcare burden in Hong Kong. This study investigated factors affecting parental acceptance of HPV vaccination after the introduction of an immunisation programme for primary school girls. We assessed parental perceptions and related factors concerning HPV vaccination for both boys and girls.
METHODS: We conducted a cross-sectional survey between December 2021 and February 2022 among parents of Primary 4 to 6 students in Hong Kong. Our self-administered online survey collected data regarding socio-demographic characteristics, awareness and knowledge of HPV vaccination, attitudes towards HPV vaccination, and acceptance of HPV vaccination. Characteristics were compared between boys' parents and girls' parents. Factors associated with vaccine acceptance were analysed by multivariate logistic regression.
RESULTS: We observed high awareness of HPV vaccination among boys' parents and girls' parents; however, they demonstrated relatively poor knowledge of HPV and the HPV vaccine. An alarming low HPV vaccination uptake rate was also observed. Attitudes towards the HPV vaccine were similar between parent groups. A majority of parents believed that the HPV vaccine was safe and effective in preventing infection. Parents of boys showed lower HPV vaccine acceptance. Factors associated with acceptance differed between parent groups.
CONCLUSION: High awareness of HPV and HPV vaccine is predictive of vaccine acceptance. Boys' parents are less likely to accept HPV vaccination and emphasis should be placed on addressing potential HPV vaccine hesitancy in this group. Public education should also aim to raise awareness of government vaccination programme, and implementation of catch-up vaccination programme to school children beyond primary school should be considered.
A none invasive, drug free collar that aids in the motility of warm blooded animals. This collar consists of magnets, copper chain or wire and beads of various compounds. Copper and magnets have been used for centuries to relieve pain and inflammation. The beads are attached to the copper chain. The copper chain ends fasten together with magnets. These magnets insure easy release of collar for safety to the animal but are strong enough to keep the collar secure and in place. The beads are for esthetic appeal and may consists of glass, plastic or semi precious stones including but not limited to onyx, tiger eye, jade or other precious or semi precious stone.
The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens complexed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific β-chain variable regions of T cell receptors, designated Vβ3, Vβ4, Vβ14 and Vβ17, which are associated with the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Also provided are means to detect, prevent and treat RA and MS. Methods of administering DNA or RNA encoding the polypeptides useful as vaccines of the present invention into the tissue cells of an individual is also provided.